Geron Q2 net loss $67.4M; RYTELO launch underway with ~160 patients treated by July 31

GERON CORP

2024-Q2 EPS reported -$0.19 revenue$1,186,000

Net loss of $67.4M ($0.10 per share) for Q2 2024, compared to $49.2M ($0.09) in Q2 2023.
RYTELO (imetelstat) commercially launched June 27, 2024; estimated ~160 patients treated as of July 31, 2024.
Total product revenue $780k for Q2; net revenue $882k (vs $29k prior year period).
Cash and marketable securities $430.4M as of June 30, 2024; FY2024 operating expenses guided to $270M-$280M.
NCCN Guidelines updated to include RYTELO as Category 1 for second-line and Category 2A for first-line LR-MDS treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.